Markt für Dyspepsiemedikamente im asiatisch-pazifischen Raum – Branchentrends und Prognose bis 2030

Inhaltsverzeichnis anfordernInhaltsverzeichnis anfordern Mit Analyst sprechen Mit Analyst sprechen Jetzt kaufenJetzt kaufen Vor dem Kauf anfragen Vorher anfragen Kostenloser Beispielbericht Kostenloser Beispielbericht

Markt für Dyspepsiemedikamente im asiatisch-pazifischen Raum – Branchentrends und Prognose bis 2030

  • Pharmaceutical
  • Publish Reports
  • May 2023
  • Asia-Pacific
  • 350 Seiten
  • Anzahl der Tabellen: 506
  • Anzahl der Abbildungen: 52

Asia Pacific Dyspepsia Drug Market

Marktgröße in Milliarden USD

CAGR :  % Diagram

Diagramm Prognosezeitraum
2024 –2030
Diagramm Marktgröße (Basisjahr)
MILLIONEN USD
Diagramm Marktgröße (Prognosejahr)
MILLIONEN USD
Diagramm CAGR
%
Diagramm Wichtige Marktteilnehmer
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>Markt für Dyspepsie-Medikamente im asiatisch-pazifischen Raum nach Typ (organische Dyspepsie, nicht-ulzerative Dyspepsie, medikamenteninduzierte Dyspepsie und andere), Behandlungstyp (medikamentös und chirurgisch), Medikamententyp (Marken- und Generika), Verschreibung (ohne und mit Rezept erhältliche Medikamente), Verabreichungsweg (oral und injizierbar), Geschlecht (männlich und weiblich), Endverbraucher (Krankenhäuser, Kliniken, Einrichtungen der häuslichen Pflege, Fachkliniken, ambulante chirurgische Zentren , akademische und staatliche Forschungsinstitute und andere), Vertriebskanal (direkte Ausschreibung und Einzelhandelsverkauf) – Branchentrends und Prognose bis 2030.

Markt für Dyspepsiemedikamente im asiatisch-pazifischen Raum

Marktanalyse und Einblicke für Dyspepsiemedikamente im asiatisch-pazifischen Raum

Der Markt für Dyspepsiemedikamente im asiatisch-pazifischen Raum dürfte im Prognosezeitraum aufgrund der zunehmenden Verbreitung von Dyspepsie und der zunehmenden Annahme ungesunder Lebensgewohnheiten wachsen. Der Markt wird auch durch die zunehmende Verbreitung von Stoffwechselstörungen beeinflusst. Der Markt für Dyspepsiemedikamente im asiatisch-pazifischen Raum dürfte jedoch durch die möglichen Nebenwirkungen der gegen Dyspepsie eingesetzten Medikamente und die zunehmende Präferenz für natürliche und pflanzliche Heilmittel beeinträchtigt werden. Die zunehmende Alterung der Bevölkerung und die Zunahme der Arzneimittelzulassungen dürften Chancen für das Marktwachstum darstellen. Strenge Vorschriften und ein Mangel an Bewusstsein für Dyspepsie in der Bevölkerung dürften jedoch das Marktwachstum behindern. 

Markt für Dyspepsiemedikamente im asiatisch-pazifischen RaumMarkt für Dyspepsiemedikamente im asiatisch-pazifischen Raum

Laut einer Analyse von Data Bridge Market Research wird der Markt für Dyspepsiemedikamente im asiatisch-pazifischen Raum im Prognosezeitraum von 2023 bis 2030 voraussichtlich mit einer durchschnittlichen jährlichen Wachstumsrate von 6,1 % wachsen.

Berichtsmetrik

Details

Prognosezeitraum

2023 bis 2030

Basisjahr

2022

Historische Jahre

2021 (Anpassbar auf 2015 – 2020)

Quantitative Einheiten

Umsatz in Tausend, Mengen in Einheiten und Preise in USD

Abgedeckte Segmente

Typ (Organische Dyspepsie, Nicht-Ulkus-Dyspepsie, Arzneimittelinduzierte Dyspepsie und andere), Behandlungstyp (Medikamente und Operationen), Arzneimitteltyp (Marken- und Generika), Verschreibung (ohne und mit verschreibungspflichtigen Arzneimitteln), Verabreichungsweg (oral und injizierbar), Geschlecht (männlich und weiblich), Endverbraucher (Krankenhäuser, Kliniken, häusliche Pflegeeinrichtungen, Fachkliniken, ambulante chirurgische Zentren, akademische und staatliche Forschungsinstitute und andere), Vertriebskanal (direkte Ausschreibung und Einzelhandelsverkauf)

Abgedeckte Länder

Japan, China, Australien, Indien, Südkorea, Singapur, Indonesien, Thailand, Malaysia, Philippinen, Neuseeland, Vietnam, Taiwan und Rest des asiatisch-pazifischen Raums

Abgedeckte Marktteilnehmer

Bayer AG, Cadila Pharmaceuticals, Sanofi, Lupin, Abbott, Perrigo Company plc, AstraZeneca, Procter & Gamble und Reckitt Benckiser unter anderem

Marktdefinition

Dyspepsie, allgemein bekannt als Verdauungsstörung, ist der Schmerz und das Unbehagen im Bauch nach dem Essen. Es ist normalerweise ein Zeichen einer zugrunde liegenden Erkrankung wie GERD (gastroösophageale Refluxkrankheit), Gallenblasen- und Geschwürerkrankung. Die Behandlung von Dyspepsie hängt von der Ursache und dem Schweregrad ab. Die Behandlung einer zugrunde liegenden Erkrankung oder eine Änderung der Medikamente einer Person kann die Dyspepsie reduzieren. Dyspepsie wird in zwei Hauptkategorien unterteilt: „organische“ und „funktionelle Dyspepsie“ (FD). Organische Ursachen für Dyspepsie sind Magengeschwüre, gastroösophageale Refluxkrankheit, Magen- oder Speiseröhrenkrebs, Bauchspeicheldrüsen- oder Gallenerkrankungen, Nahrungsmittel- oder Arzneimittelunverträglichkeiten und andere infektiöse oder systemische Erkrankungen. Funktionelle Dyspepsie (dis-PEP-see-uh) ist ein Begriff für wiederkehrende Symptome einer Magenverstimmung, die keine offensichtliche Ursache haben. Funktionelle Dyspepsie wird auch als nicht-ulzeröse Dyspepsie bezeichnet.

Dynamik des Marktes für Dyspepsiemedikamente im asiatisch-pazifischen Raum

In diesem Abschnitt geht es um das Verständnis der Markttreiber, Vorteile, Chancen, Einschränkungen und Herausforderungen. All dies wird im Folgenden ausführlich erläutert:

TREIBER

  • Zunehmende Prävalenz von Dyspepsie

Dyspepsie, allgemein als Verdauungsstörung bekannt, ist eine Magen-Darm-Störung, die Millionen von Menschen im asiatisch-pazifischen Raum betrifft. Es handelt sich um eine Erkrankung, die Unbehagen, Schmerzen und ein Völlegefühl oder Blähungen im Oberbauch verursacht. Dyspepsie kann durch eine Vielzahl von Faktoren verursacht werden, wie z. B. zu schnelles Essen, den Verzehr von scharfen oder fettigen Speisen oder als Nebenwirkung von Medikamenten.

Die zunehmende Verbreitung von Dyspepsie ist einer der wichtigsten Antriebsfaktoren für das Wachstum des Marktes für Dyspepsie-Medikamente. Die steigende Inzidenz von Dyspepsie kann auf mehrere Faktoren zurückgeführt werden, wie etwa Veränderungen des Lebensstils, der Ernährungsgewohnheiten und eine alternde Bevölkerung. Mit zunehmendem Alter sind Menschen anfälliger für Verdauungsprobleme, einschließlich Dyspepsie. Mit der wachsenden Zahl älterer Erwachsener steigt die Nachfrage nach Dyspepsie-Medikamenten.

Darüber hinaus verursachen auch verschiedene Verdauungskrankheiten wie Reizdarmsyndrom, Gastroparese, Gastritis und Magengeschwüre Dyspepsie, da die Prävalenz der genannten Krankheiten zunimmt. Daher wird erwartet, dass die zunehmende Prävalenz von Dyspepsie und anderen Verdauungsstörungen, die Dyspepsie verursachen, als Wachstumsmotor für den Markt fungiert. Der Einsatz von Dyspepsie-Medikamenten zur Linderung der Symptome von Dyspepsie und zur Behandlung der Dyspepsie hat das Potenzial, die Behandlungsergebnisse der Patienten zu verbessern und die Belastung durch Dyspepsie zu verringern. Daher treibt die zunehmende Prävalenz von Dyspepsie die Nachfrage nach Dyspepsie-Medikamenten weltweit an, um die Inzidenz und Prävalenz der Dyspepsie in der Bevölkerung zu erhöhen.

  • Anstieg der Annahme eines ungesunden Lebensstils

In den letzten Jahren hat die Annahme eines ungesunden Lebensstils zugenommen, was zu einer Zunahme der Dyspepsie geführt hat. Ungesunde Lebensgewohnheiten wie eine Ernährung mit hohem Anteil verarbeiteter Lebensmittel, Bewegungsmangel und übermäßiger Alkoholkonsum können alle zu Dyspepsie beitragen.

Infolgedessen ist die Nachfrage nach Dyspepsie-Medikamenten entsprechend gestiegen, da die Menschen nach Linderung ihrer Symptome suchen. Der Markt für Dyspepsie-Medikamente hat auf diese Nachfrage mit einer Vielzahl von Medikamenten reagiert, darunter Protonenpumpenhemmer, H2-Rezeptorantagonisten und Antazida.

Der Anstieg ungesunder Lebensgewohnheiten kann auf mehrere Faktoren zurückgeführt werden, darunter veränderte Ernährungsgewohnheiten, steigende Stresslevel und eine sitzende Lebensweise. Das moderne Leben ist oft durch lange Arbeitszeiten, hohe Stresslevel und den einfachen Zugang zu Fast Food und anderen ungesunden Optionen gekennzeichnet. Diese Faktoren können zu Dyspepsie und anderen damit verbundenen Erkrankungen wie der gastroösophagealen Refluxkrankheit (GERD) beitragen.

Zusammenfassend lässt sich sagen, dass Dyspepsie eine weit verbreitete Erkrankung ist, die durch eine Vielzahl von Faktoren verursacht werden kann, darunter auch ungesunde Lebensgewohnheiten. Die zunehmende Annahme ungesunder Lebensgewohnheiten hat zu einer Zunahme der Dyspepsie-Prävalenz beigetragen, und die Nachfrage nach wirksamen Dyspepsie-Medikamenten ist entsprechend gestiegen, was voraussichtlich als Wachstumsmotor für den Markt wirken wird.

GELEGENHEIT

  • Wachsende, alternde Bevölkerung

Schätzungen zufolge wird die Zahl der über 65-jährigen Menschen bis zum Jahr 2050 voraussichtlich 1,5 Milliarden erreichen. Dies zeigt, dass die Weltbevölkerung rasch altert und immer älter wird. Mit zunehmendem Alter steigt das Risiko, chronische Erkrankungen zu entwickeln. Dazu gehören Verdauungsstörungen wie Dyspepsie, die als Folge des Alterns auftreten können.

Die wachsende und alternde Bevölkerung bietet erhebliche Chancen für eine Ausweitung des Marktes für Dyspepsie-Medikamente. Da immer mehr Menschen Probleme mit ihrem Verdauungssystem haben, besteht ein wachsender Bedarf an wirksamen Behandlungen, die die Schwere ihrer Symptome verringern und ihre allgemeine Lebensqualität verbessern können.

Darüber hinaus muss die Behandlung von Dyspepsie möglicherweise speziell auf die Anforderungen einer alternden Bevölkerung zugeschnitten werden. Ältere Menschen können mehrere chronische Erkrankungen haben und gleichzeitig mehrere Medikamente einnehmen, was die Wahrscheinlichkeit negativer Wechselwirkungen und Nebenwirkungen erhöhen kann. Daher besteht ein Bedarf an Medikamenten gegen Dyspepsie, die bei der Verabreichung an ältere Erwachsene sowohl risikofrei als auch wirksam sind. Und mit zunehmendem Alter verlieren Menschen auch ihre körperliche Stärke und ihr Immunsystem, was zu einer zunehmenden Verbreitung mehrerer Magen-Darm-Erkrankungen, einschließlich Dyspepsie, führt.

Daher ist zu erwarten, dass die zunehmende Alterung der Bevölkerung, die zu Dyspepsie und deren Symptomen führt, und die Vorliebe der Menschen für vorbeugende Gesundheitsfürsorge Chancen für das Wachstum des Marktes für Dyspepsie-Medikamente bieten werden.

ZURÜCKHALTUNG/HERAUSFORDERUNG

  • Mangelndes Bewusstsein für Dyspepsie in der Bevölkerung

Der Fachkräftemangel wirkt sich bereits jetzt auf das Land aus, da immer mehr Menschen mehr als sechs Monate auf ihre zahnärztliche Behandlung warten müssen. Aufgrund des technischen Fortschritts, der grundlegenden Infrastruktur und mehrerer anderer Faktoren herrscht in Schwellen- oder Entwicklungsländern ein Mangel an qualifizierten Fachkräften auf dem Gebiet der Dyspepsie-Medikamente.

Der Mangel an qualifizierten Fachkräften ist teilweise auf die strenge Ausbildung und das Training zurückzuführen, die erforderlich sind, um ein Zahnarzt zu werden, sowie auf den wettbewerbsintensiven Arbeitsmarkt. Darüber hinaus benötigen qualifizierte Zahnärzte mehr offiziell ausgebildete, zugelassene Zahnarzthelfer, um den Zugang zur Zahnpflege aufrechtzuerhalten und zu verbessern, damit diese fortschrittliche technologische Systeme wie Dyspepsie-Medikamentensysteme bedienen und ausführen können.

In den Schwellenländern mangelt es an qualifizierten Fachkräften, die die neuen Technologien nicht effektiv einsetzen können. Dies könnte zu einer Herausforderung auf dem Markt für neue Technologien führen, da diese Länder den Beginn technologisch getriebener Fortschritte auf dem Markt verzögern.

Jüngste Entwicklungen

  • Im April 2023 gab Sanofi den Abschluss der Übernahme von Prevention Bio, Inc. bekannt. Diese Übernahme hat dem Unternehmen beim Ausbau seines Geschäfts im Bereich Allgemeinmedizin geholfen.
  • Im Juli 2022 gab ANI Pharmaceuticals, Inc. den Kauf von vier verkürzten Anträgen auf Zulassung neuer Arzneimittel (ANDAs) von Oakrum Pharma, LLC, einem privaten biopharmazeutischen Unternehmen, bekannt.

Marktsegmentierung für Dyspepsiemedikamente im asiatisch-pazifischen Raum

Der Markt für Dyspepsiemedikamente im asiatisch-pazifischen Raum ist segmentiert nach Typ, Behandlungsart, Medikamententyp, Verschreibung, Verabreichungsweg, Geschlecht, Endverbraucher und Vertriebskanal. Das Wachstum zwischen den Segmenten hilft Ihnen, Nischenwachstumsbereiche und Strategien zur Marktbearbeitung zu analysieren und Ihre wichtigsten Anwendungsbereiche und die Unterschiede in Ihren Zielmärkten zu bestimmen.

Typ

  • Nicht-ulzeröse Dyspepsie
  •  Organische Dyspepsie
  •  Arzneimittelinduzierte Dyspepsie
  •  Sonstiges

Je nach Typ ist der Markt für Dyspepsiemedikamente im asiatisch-pazifischen Raum in organische Dyspepsie, nicht-ulzerative Dyspepsie, medikamenteninduzierte Dyspepsie und andere unterteilt.

Behandlungstyp

  • Medikamente
  • Operation

Basierend auf der Behandlungsart ist der Markt für Dyspepsiemedikamente im asiatisch-pazifischen Raum in medikamentöse und chirurgische Eingriffe unterteilt.

Arzneimitteltyp

  • Gebrandmarkt
  • Generisch

Basierend auf dem Medikamententyp ist der Markt für Dyspepsiemedikamente im asiatisch-pazifischen Raum in Generika und Markenmedikamente unterteilt.

Rezept

  • Ohne verschreibungspflichtige Medikamente
  • Verschreibungspflichtige Medikamente

Basierend auf der Verschreibung ist der Markt für Dyspepsiemedikamente im asiatisch-pazifischen Raum in rezeptfreie und rezeptpflichtige Medikamente segmentiert.

Verabreichungsweg

  • Oral
  • Injektion

Basierend auf der Verabreichungsart ist der Markt für Dyspepsiemedikamente im asiatisch-pazifischen Raum in orale und injizierbare Mittel unterteilt.

Geschlecht

  • Männlich
  • Weiblich

Basierend auf dem Geschlecht ist der Markt für Dyspepsiemedikamente im asiatisch-pazifischen Raum in männlich und weiblich unterteilt.

Endbenutzer

  • Krankenhäuser
  • Kliniken
  • Einstellungen für die häusliche Pflege
  • Spezialkliniken
  • Ambulante Zentren
  • Akademische und staatliche Forschungsinstitute
  • Sonstiges

Basierend auf dem Endverbraucher ist der Markt für Dyspepsie-Medikamente im asiatisch-pazifischen Raum in Krankenhäuser, Kliniken, Einrichtungen der häuslichen Pflege, Fachkliniken, ambulante chirurgische Zentren, akademische und staatliche Forschungsinstitute und andere unterteilt.

Vertriebskanal

  • Direkte Ausschreibung
  • Einzelhandelsumsätze

Basierend auf dem Vertriebskanal ist der Markt für Dyspepsiemedikamente im asiatisch-pazifischen Raum in Direktausschreibungen und Einzelhandelsverkäufe unterteilt.

Markt für Dyspepsie-Medikamente

Regionale Analyse/Einblicke zum Markt für Dyspepsiemedikamente im asiatisch-pazifischen Raum

Der Markt für Dyspepsiemedikamente im asiatisch-pazifischen Raum wird analysiert und es werden Erkenntnisse und Trends zur Marktgröße basierend auf Typ, Behandlungsart, Medikamententyp, Verschreibung, Verabreichungsweg, Geschlecht, Endverbraucher und Vertriebskanal bereitgestellt.

Die in diesem Marktbericht abgedeckten Länder sind Japan, China, Australien, Indien, Südkorea, Singapur, Indonesien, Thailand, Malaysia, Philippinen, Neuseeland, Vietnam, Taiwan und der restliche asiatisch-pazifische Raum.

Aufgrund der steigenden Zahl von Produktzulassungen im Land wird Japan voraussichtlich den Markt für Dyspepsie-Medikamente im asiatisch-pazifischen Raum dominieren.

Der Länderabschnitt des Berichts enthält auch einzelne marktbeeinflussende Faktoren und Änderungen der Marktregulierung, die sich auf die aktuellen und zukünftigen Trends des Marktes auswirken. Datenpunkte wie die Analyse der nachgelagerten und vorgelagerten Wertschöpfungskette, technische Trends, Porters Fünf-Kräfte-Analyse und Fallstudien sind einige der Hinweise, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Bei der Bereitstellung einer Prognoseanalyse der Länderdaten werden auch die Präsenz und Verfügbarkeit von Marken aus dem asiatisch-pazifischen Raum und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen inländischer Zölle und Handelsrouten berücksichtigt.

Wettbewerbsumfeld und Marktanteilsanalyse für Dyspepsiemedikamente im asiatisch-pazifischen Raum

Die Wettbewerbslandschaft des Marktes für Dyspepsiemedikamente im asiatisch-pazifischen Raum liefert Einzelheiten zu den Wettbewerbern. Die enthaltenen Einzelheiten umfassen Unternehmensübersicht, Unternehmensfinanzen, erzielten Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Präsenz im asiatisch-pazifischen Raum, Produktionsstandorte und -anlagen, Produktionskapazitäten, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktbreite und -umfang sowie Anwendungsdominanz. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus der Unternehmen auf den Markt.

Zu den wichtigsten Marktteilnehmern auf diesem Markt zählen unter anderem Bayer AG, Cadila Pharmaceuticals, Sanofi, Lupin, Abbott, Perrigo Company plc, AstraZeneca, Procter & Gamble und Reckitt Benckiser.


SKU-

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

  • Interaktives Datenanalyse-Dashboard
  • Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
  • Zugriff für Research-Analysten für Anpassungen und Abfragen
  • Konkurrenzanalyse mit interaktivem Dashboard
  • Aktuelle Nachrichten, Updates und Trendanalyse
  • Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Demo anfordern

Inhaltsverzeichnis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA-PACIFIC DYSPEPSIA DRUG MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END-USER COVERAGE GRID

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

5 EPIDEMIOLOGY

6 PROBLEMS IN THE MANAGEMENT OF DYSPEPSIA

7 INDUSTRY INSIGHTS:

8 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, REGULATION

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 INCREASING PREVALENCE OF DYSPEPSIA

9.1.2 RISE IN THE ADOPTION OF UNHEALTHY LIFESTYLE

9.1.3 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS

9.2 RESTRAINTS

9.2.1 POSSIBLE SIDE EFFECTS OF THE DRUGS USED FOR DYSPEPSIA

9.2.2 INCREASING PREFERENCE FOR NATURAL AND HERBAL REMEDIES

9.3 OPPORTUNITIES

9.3.1 GROWING AGING POPULATION

9.3.2 RISE IN THE DRUG APPROVAL

9.4 CHALLENGES

9.4.1 LACK OF AWARENESS ABOUT DYSPEPSIA AMONG THE POPULATION

9.4.2 STRINGENT REGULATIONS

10 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TYPE

10.1 OVERVIEW

10.2 NON-ULCER DYSPEPSIA

10.3 ORGANIC DYSPEPSIA

10.4 DRUG INDUCED DYSPEPSIA

10.5 OTHERS

11 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE

11.1 OVERVIEW

11.2 MEDICATION

11.2.1 DRUGS

11.2.1.1 ANTACIDS

11.2.1.1.1 PROTON PUMP INHIBITORS (PPI’S)

11.2.1.1.1.1 OMEPRAZOLE

11.2.1.1.1.2 LANSOPRAZOLE

11.2.1.1.1.3 ESOMEPRAZOLE

11.2.1.1.1.4 OTHERS

11.2.1.1.2 H2 BLOCKERS

11.2.1.1.2.1 CIMETIDINE

11.2.1.1.2.2 FAMOTIDINE

11.2.1.1.2.3 NIZATIDINE

11.2.1.1.2.4 RANITIDINE

11.2.1.1.2.5 OTHERS

11.2.1.2 GASTRIC PROKINETIC GENDERNTS

11.2.1.2.1 MOSAPRIDE CITRATE

11.2.1.2.2 METOCLOPRAMIDE

11.2.1.2.3 CISAPRIDE

11.2.1.2.4 ITOPRIDE HYDROCHLORIDE

11.2.1.2.5 DOMPERIDONE

11.2.1.2.6 OTHERS

11.2.1.3 ANTIBIOTICS

11.2.1.3.1 REFAXIMIN

11.2.1.3.2 AMOXICILLIN

11.2.1.3.3 CLARITHROMYCIN

11.2.1.3.4 METRONIDAZOLE

11.2.1.3.5 LEVOFLOXACIN

11.2.1.3.6 TETRACYCLINE

11.2.1.3.7 OTHERS

11.2.1.4 OTHERS

11.2.2 NON- DRUGS

11.2.2.1 PROBIOTICS

11.2.2.1.1 LACTOBACILLUS

11.2.2.1.2 BIFIDOBACTERIUM

11.2.2.1.3 BACILLUS

11.2.2.1.4 STREPTOCOCCUS

11.2.2.1.5 OTHERS

11.2.2.2 PREBIOTICS

11.3 SURGERY

12 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DRUG TYPE

12.1 OVERVIEW

12.2 GENERIC

12.3 BRANDED

13 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY PRESCRIPTION

13.1 OVERVIEW

13.2 WITHOUT PRESCRIPTION DRUGS

13.3 PRESCRIPTION DRUGS

14 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION

14.1 OVERVIEW

14.2 ORAL

14.2.1 TABLETS

14.2.2 CAPSULES

14.3 INJECTABLE

15 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY GENDER

15.1 OVERVIEW

15.2 FEMALE

15.2.1 30-50 YEARS

15.2.2 MORE THAN 50 YEARS

15.2.3 AGE LESS THAN 30

15.3 MALE

15.3.1 30-50 YEARS

15.3.2 MORE THAN 50 YEARS

15.3.3 AGE LESS THAN 30

16 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY END USER

16.1 OVERVIEW

16.2 HOSPITALS

16.2.1 TYPE

16.2.1.1 PUBLIC

16.2.1.2 PRIVATE

16.2.2 TIER

16.2.2.1 TIER 3

16.2.2.2 TIER 2

16.2.2.3 TEIR 1

16.3 CLINICS

16.4 HOMECARE SETTINGS

16.5 SPECIALTY CLINICS

16.6 AMBULATORY CENTERS

16.7 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES

16.8 OTHERS

17 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL

17.1 OVERVIEW

17.2 RETAIL SALES

17.2.1 REATIL PHARMACY

17.2.2 HOSPITAL PHARMACY

17.2.3 ONLINE PHARMACY

17.3 DIRECT TENDER

18 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY REGION

18.1 ASIA-PACIFIC

18.1.1 JAPAN

18.1.2 CHINA

18.1.3 SOUTH KOREA

18.1.4 INDIA

18.1.5 AUSTRALIA

18.1.6 NEW ZEALAND

18.1.7 SINGAPORE

18.1.8 THAILAND

18.1.9 INDONESIA

18.1.10 MALAYSIA

18.1.11 PHILIPPINES

18.1.12 VIETNAM

18.1.13 TAIWAN

18.1.14 REST OF ASIA-PACIFIC

19 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, COMPANY LANDSCAPE

19.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

20 SWOT ANALYSIS

21 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, COMPANY PROFILINGS

21.1 SANOFI

21.1.1 COMPANY SNAPSHOT

21.1.2 REVENUE ANALYSIS

21.1.3 COMPANY SHARE ANALYSIS

21.1.4 PRODUCT PORTFOLIO

21.1.5 RECENT DEVELOPMENT

21.2 LUPIN

21.2.1 COMPANY SNAPSHOT

21.2.2 REVENUE ANALYSIS

21.2.3 COMPANY SHARE ANALYSIS

21.2.4 PRODUCT PORTFOLIO

21.2.5 RECENT DEVELOPMENTS

21.3 MANKIND PHARMA

21.3.1 COMPANY SNAPSHOT

21.3.2 REVENUE ANALYSIS

21.3.3 COMPANY SHARE ANALYSIS

21.3.4 PRODUCT PORTFOLIO

21.3.5 RECENT DEVELOPMENT

21.4 ASTRAZENECA

21.4.1 COMPANY SNAPSHOT

21.4.2 REVENUE ANALYSIS

21.4.3 COMPANY SHARE ANALYSIS

21.4.4 PRODUCT PORTFOLIO

21.4.5 RECENT DEVELOPMENT

21.5 BAYER AG

21.5.1 COMPANY SNAPSHOT

21.5.2 REVENUE ANALYSIS

21.5.3 COMPANY SHARE ANALYSIS

21.5.4 PRODUCT PORTFOLIO

21.5.5 RECENT DEVELOPMENT

21.6 ABBOTT

21.6.1 COMPANY SNAPSHOT

21.6.2 REVENUE ANALYSIS

21.6.3 PRODUCT PORTFOLIO

21.6.4 RECENT DEVELOPMENT

21.7 ANI PHARMACEUTICALS, INC.

21.7.1 COMPANY SNAPSHOT

21.7.2 REVENUE ANALYSIS

21.7.3 PRODUCT PORTFOLIO

21.7.4 RECENT DEVELOPMENT

21.8 AOSAIKANG PHARMACEUTICAL CO., LTD.

21.8.1 COMPANY SNAPSHOT

21.8.2 REVENUE ANALYSIS

21.8.3 PRODUCT PORTFOLIO

21.8.4 RECENT DEVELOPMENT

21.9 ASTERISK LABORATORIES (I) PVT. LTD

21.9.1 COMPANY SNAPSHOT

21.9.2 PRODUCT PORTFOLIO

21.9.3 RECENT DEVELOPMENT

21.1 CADILA PHARMACEUTICALS

21.10.1 COMPANY SNAPSHOT

21.10.2 REVENUE ANALYSIS

21.10.3 COMPANY SHARE ANALYSIS

21.10.4 PRODUCT PORTFOLIO

21.10.5 RECENT DEVELOPMENT

21.11 HANMI PHARM. CO., LTD.

21.11.1 COMPANY SNAPSHOT

21.11.2 REVENUE ANALYSIS

21.11.3 PRODUCT PORTFOLIO

21.11.4 RECENT DEVELOPMENT

21.12 MCNEIL CONSUMER PHARMACEUTICALS CO. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

21.12.1 COMPANY SNAPSHOT

21.12.2 REVENUE ANALYSIS

21.12.3 PRODUCT PORTFOLIO

21.12.4 RECENT DEVELOPMENT

21.13 OTSUKA PHARMACEUTICAL CO., LTD.

21.13.1 COMPANY SNAPSHOT

21.13.2 REVENUE ANALYSIS

21.13.3 PRODUCT PORTFOLIO

21.13.4 RECENT DEVELOPMENT

21.14 PERRIGO COMPANY PLC

21.14.1 COMPANY SNAPSHOT

21.14.2 REVENUE ANALYSIS

21.14.3 PRODUCT PORTFOLIO

21.14.4 RECENT DEVELOPMENT

21.15 PRESTIGE CONSUMER HEALTHCARE, INC.

21.15.1 COMPANY SNAPSHOT

21.15.2 REVENUE ANALYSIS

21.15.3 PRODUCT PORTFOLIO

21.15.4 RECENT DEVELOPMENT

21.16 PROCTER & GAMBLE

21.16.1 COMPANY SNAPSHOT

21.16.2 REVENUE ANALYSIS

21.16.3 PRODUCT PORTFOLIO

21.16.4 RECENT DEVELOPMENT

21.17 RECKITT BENCKISER.

21.17.1 COMPANY SNAPSHOT

21.17.2 REVENUE ANALYSIS

21.17.3 PRODUCT PORTFOLIO

21.17.4 RECENT DEVELOPMENT

21.18 REDHILL BIOPHARMA LTD

21.18.1 COMPANY SNAPSHOT

21.18.2 REVENUE ANALYSIS

21.18.3 PRODUCT PORTFOLIO

21.18.4 RECENT DEVELOPMENT

21.19 SALIX PHARMACEUTICALS OR ITS AFFILIATES (SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)

21.19.1 COMPANY SNAPSHOT

21.19.2 REVENUE ANALYSIS

21.19.3 PRODUCT PORTFOLIO

21.19.4 RECENT DEVELOPMENT

21.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED

21.20.1 COMPANY SNAPSHOT

21.20.2 REVENUE ANALYSIS

21.20.3 PRODUCT PORTFOLIO

21.20.4 RECENT DEVELOPMENTS

21.21 WOODWARD PHARMA

21.21.1 COMPANY SNAPSHOT

21.21.2 PRODUCT PORTFOLIO

21.21.3 RECENT DEVELOPMENT

21.22 ZERIA PHARMACEUTICAL CO., LTD.

21.22.1 COMPANY SNAPSHOT

21.22.2 REVENUE ANALYSIS

21.22.3 PRODUCT PORTFOLIO

21.22.4 RECENT DEVELOPMENT

22 QUESTIONNAIRE

23 RELATED REPORTS

Tabellenverzeichnis

TABLE 1 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 2 ASIA-PACIFIC NON-ULCER DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 3 ASIA-PACIFIC ORGANIC DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 4 ASIA-PACIFIC DRUG INDUCED DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 5 ASIA-PACIFIC OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 6 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 7 ASIA-PACIFIC MEDICATION IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 8 ASIA-PACIFIC MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 9 ASIA-PACIFIC DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 10 ASIA-PACIFIC ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 11 ASIA-PACIFIC PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 12 ASIA-PACIFIC H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 13 ASIA-PACIFIC GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 14 ASIA-PACIFIC ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 15 ASIA-PACIFIC NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 16 ASIA-PACIFIC PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 17 ASIA-PACIFIC SURGERY IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 18 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 19 ASIA-PACIFIC GENERIC IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 20 ASIA-PACIFIC BRANDED IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 21 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 22 ASIA-PACIFIC WITHOUT PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 23 ASIA-PACIFIC PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 24 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 25 ASIA-PACIFIC ORAL IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 26 ASIA-PACIFIC ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 27 ASIA-PACIFIC INJECTABLE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 28 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 29 ASIA-PACIFIC FEMALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 30 ASIA-PACIFIC FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 31 ASIA-PACIFIC MALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 32 ASIA-PACIFIC MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 33 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 34 ASIA-PACIFIC HOSPITALS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 35 ASIA-PACIFIC HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 36 ASIA-PACIFIC HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 37 ASIA-PACIFIC CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 38 ASIA-PACIFIC HOMECARE SETTINGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 39 ASIA-PACIFIC SPECIALTY CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 40 ASIA-PACIFIC AMBULATORY CENTERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 41 ASIA-PACIFIC ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 42 ASIA-PACIFIC OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 43 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 44 ASIA-PACIFIC RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 45 ASIA-PACIFIC RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 46 ASIA-PACIFIC DIRECT TENDER IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 47 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 48 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 49 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 50 ASIA-PACIFIC MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 51 ASIA-PACIFIC DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 52 ASIA-PACIFIC ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 53 ASIA-PACIFIC PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 54 ASIA-PACIFIC PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 55 ASIA-PACIFIC H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030, (USD THOUSANDS )

TABLE 56 ASIA-PACIFIC H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 57 ASIA-PACIFIC GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 58 ASIA-PACIFIC GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 59 ASIA-PACIFIC ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 60 ASIA-PACIFIC ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 61 ASIA-PACIFIC NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 62 ASIA-PACIFIC PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 63 ASIA-PACIFIC PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 64 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 65 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 66 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 67 ASIA-PACIFIC ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 68 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 69 ASIA-PACIFIC FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 70 ASIA-PACIFIC MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 71 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 72 ASIA-PACIFIC HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 73 ASIA-PACIFIC HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 74 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 75 ASIA-PACIFIC RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 76 JAPAN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 77 JAPAN DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 78 JAPAN MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 79 JAPAN DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 80 JAPAN ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 81 JAPAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 82 JAPAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 83 JAPAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 84 JAPAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 85 JAPAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 86 JAPAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 87 JAPAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 88 JAPAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 89 JAPAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 90 JAPAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 91 JAPAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 92 JAPAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 93 JAPAN NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 94 JAPAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 95 JAPAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 96 JAPAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 97 JAPAN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 98 JAPAN DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 99 JAPAN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 100 JAPAN ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 101 JAPAN DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 102 JAPAN FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 103 JAPAN MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 104 JAPAN DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 105 JAPAN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 106 JAPAN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 107 JAPAN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 108 JAPAN RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 109 .CHINA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 110 CHINA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 111 CHINA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 112 CHINA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 113 CHINA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 114 CHINA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 115 CHINA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 116 CHINA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 117 CHINA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 118 CHINA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 119 CHINA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 120 CHINA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 121 CHINA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 122 CHINA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 123 CHINA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 124 CHINA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 125 CHINA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 126 CHINA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 127 CHINA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 128 CHINA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 129 CHINA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 130 CHINA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 131 CHINA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 132 CHINA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 133 CHINA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 134 CHINA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 135 CHINA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 136 CHINA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 137 CHINA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 138 CHINA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 139 CHINA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 140 CHINA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 141 CHINA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 142 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 143 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 144 SOUTH KOREA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 145 SOUTH KOREA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 146 SOUTH KOREA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 147 SOUTH KOREA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 148 SOUTH KOREA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 149 SOUTH KOREA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 150 SOUTH KOREA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 151 SOUTH KOREA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 152 SOUTH KOREA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 153 SOUTH KOREA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 154 SOUTH KOREA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 155 SOUTH KOREA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 156 SOUTH KOREA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 157 SOUTH KOREA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 158 SOUTH KOREA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 159 SOUTH KOREA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 160 SOUTH KOREA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 161 SOUTH KOREA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 162 SOUTH KOREA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 163 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 164 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 165 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 166 SOUTH KOREA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 167 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 168 SOUTH KOREA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 169 SOUTH KOREA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 170 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 171 SOUTH KOREA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 172 SOUTH KOREA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 173 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 174 SOUTH KOREA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 175 INDIA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 176 INDIA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 177 INDIA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 178 INDIA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 179 INDIA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 180 INDIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 181 INDIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 182 INDIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 183 INDIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 184 INDIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 185 INDIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 186 INDIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 187 INDIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 188 INDIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 189 INDIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 190 INDIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 191 INDIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 192 INDIA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 193 INDIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 194 INDIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 195 INDIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 196 INDIA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 197 INDIA BRANDED IN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 198 INDIA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 199 INDIA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 200 INDIA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 201 INDIA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 202 INDIA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 203 INDIA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 204 INDIA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 205 INDIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 206 INDIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 207 INDIA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 208 INDIA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 209 AUSTRALIA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 210 AUSTRALIA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 211 AUSTRALIA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 212 AUSTRALIA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 213 AUSTRALIA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 214 AUSTRALIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 215 AUSTRALIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 216 AUSTRALIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 217 AUSTRALIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 218 AUSTRALIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 219 AUSTRALIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 220 AUSTRALIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 221 AUSTRALIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 222 AUSTRALIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 223 AUSTRALIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 224 AUSTRALIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 225 AUSTRALIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 226 AUSTRALIA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 227 AUSTRALIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 228 AUSTRALIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 229 AUSTRALIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 230 AUSTRALIA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 231 AUSTRALIA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 232 AUSTRALIA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 233 AUSTRALIA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 234 AUSTRALIA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 235 AUSTRALIA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 236 AUSTRALIA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 237 AUSTRALIA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 238 AUSTRALIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 239 AUSTRALIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 240 AUSTRALIA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 241 AUSTRALIA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 242 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 243 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 244 NEW ZEALAND MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 245 NEW ZEALAND DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 246 NEW ZEALAND ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 247 NEW ZEALAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 248 NEW ZEALAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 249 NEW ZEALAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 250 NEW ZEALAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 251 NEW ZEALAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 252 NEW ZEALAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 253 NEW ZEALAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 254 NEW ZEALAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 255 NEW ZEALAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 256 NEW ZEALAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 257 NEW ZEALAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 258 NEW ZEALAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 259 NEW ZEALAND NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 260 NEW ZEALAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 261 NEW ZEALAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 262 NEW ZEALAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 263 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 264 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 265 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 266 NEW ZEALAND ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 267 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 268 NEW ZEALAND FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 269 NEW ZEALAND MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 270 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 271 NEW ZEALAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 272 NEW ZEALAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 273 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 274 NEW ZEALAND RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 275 SINGAPORE DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 276 SINGAPORE DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 277 SINGAPORE MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 278 SINGAPORE DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 279 SINGAPORE ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 280 SINGAPORE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 281 SINGAPORE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 282 SINGAPORE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 283 SINGAPORE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 284 SINGAPORE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 285 SINGAPORE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 286 SINGAPORE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 287 SINGAPORE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 288 SINGAPORE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 289 SINGAPORE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 290 SINGAPORE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 291 SINGAPORE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 292 SINGAPORE NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 293 SINGAPORE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 294 SINGAPORE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 295 SINGAPORE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 296 SINGAPORE DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 297 SINGAPORE DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 298 SINGAPORE DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 299 SINGAPORE ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 300 SINGAPORE DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 301 SINGAPORE FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 302 SINGAPORE MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 303 SINGAPORE DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 304 SINGAPORE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 305 SINGAPORE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 306 SINGAPORE DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 307 SINGAPORE RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 308 THAILAND DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 309 THAILAND DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 310 THAILAND MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 311 THAILAND DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 312 THAILAND ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 313 THAILAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 314 THAILAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 315 THAILAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 316 THAILAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 317 THAILAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 318 THAILAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 319 THAILAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 320 THAILAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 321 THAILAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 322 THAILAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 323 THAILAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 324 THAILAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 325 THAILAND NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 326 THAILAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 327 THAILAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 328 THAILAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 329 THAILAND DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 330 THAILAND DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 331 THAILAND DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 332 THAILAND ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 333 THAILAND DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 334 THAILAND FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 335 THAILAND MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 336 THAILAND DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 337 THAILAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 338 THAILAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 339 THAILAND DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 340 THAILAND RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 341 INDONESIA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 342 INDONESIA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 343 INDONESIA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 344 INDONESIA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 345 INDONESIA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 346 INDONESIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 347 INDONESIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 348 INDONESIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 349 INDONESIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 350 INDONESIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 351 INDONESIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 352 INDONESIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 353 INDONESIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 354 INDONESIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 355 INDONESIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 356 INDONESIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 357 INDONESIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 358 INDONESIA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 359 INDONESIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 360 INDONESIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 361 INDONESIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 362 INDONESIA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 363 INDONESIA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 364 INDONESIA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 365 INDONESIA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 366 INDONESIA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 367 INDONESIA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 368 INDONESIA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 369 INDONESIA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 370 INDONESIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 371 INDONESIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 372 INDONESIA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 373 INDONESIA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 374 MALAYSIA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 375 MALAYSIA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 376 MALAYSIA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 377 MALAYSIA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 378 MALAYSIA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 379 MALAYSIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 380 MALAYSIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 381 MALAYSIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 382 MALAYSIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 383 MALAYSIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 384 MALAYSIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 385 MALAYSIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 386 MALAYSIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 387 MALAYSIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 388 MALAYSIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 389 MALAYSIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 390 MALAYSIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 391 MALAYSIA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 392 MALAYSIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 393 MALAYSIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 394 MALAYSIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 395 MALAYSIA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 396 MALAYSIA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 397 MALAYSIA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 398 MALAYSIA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 399 MALAYSIA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 400 MALAYSIA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 401 MALAYSIA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 402 MALAYSIA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 403 MALAYSIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 404 MALAYSIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 405 MALAYSIA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 406 MALAYSIA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 407 PHILIPPINES DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 408 PHILIPPINES DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 409 PHILIPPINES MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 410 PHILIPPINES DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 411 PHILIPPINES ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 412 PHILIPPINES PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 413 PHILIPPINES PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 414 PHILIPPINES PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 415 PHILIPPINES H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 416 PHILIPPINES H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 417 PHILIPPINES H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 418 PHILIPPINES GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 419 PHILIPPINES GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 420 PHILIPPINES GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 421 PHILIPPINES ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 422 PHILIPPINES ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 423 PHILIPPINES ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 424 PHILIPPINES NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 425 PHILIPPINES PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 426 PHILIPPINES PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 427 PHILIPPINES PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 428 PHILIPPINES DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 429 PHILIPPINES DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 430 PHILIPPINES DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 431 PHILIPPINES ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 432 PHILIPPINES DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 433 PHILIPPINES FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 434 PHILIPPINES MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 435 PHILIPPINES DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 436 PHILIPPINES HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 437 PHILIPPINES HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 438 PHILIPPINES DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 439 PHILIPPINES RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 440 VIETNAM DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 441 VIETNAM DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 442 VIETNAM MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 443 VIETNAM DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 444 VIETNAM ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 445 VIETNAM PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 446 VIETNAM PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 447 VIETNAM PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 448 VIETNAM H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 449 VIETNAM H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 450 VIETNAM H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 451 VIETNAM GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 452 VIETNAM GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 453 VIETNAM GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 454 VIETNAM ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 455 VIETNAM ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 456 VIETNAM ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 457 VIETNAM NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 458 VIETNAM PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 459 VIETNAM PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 460 VIETNAM PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 461 VIETNAM DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 462 VIETNAM DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 463 VIETNAM DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 464 VIETNAM ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 465 VIETNAM DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 466 VIETNAM FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 467 VIETNAM MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 468 VIETNAM DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 469 VIETNAM HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 470 VIETNAM HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 471 VIETNAM DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 472 VIETNAM RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 473 TAIWAN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 474 TAIWAN DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 475 TAIWAN MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 476 TAIWAN DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 477 TAIWAN ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 478 TAIWAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 479 TAIWAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 480 TAIWAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 481 TAIWAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 482 TAIWAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 483 TAIWAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 484 TAIWAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 485 TAIWAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 486 TAIWAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 487 TAIWAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 488 TAIWAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 489 TAIWAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 490 TAIWAN NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 491 TAIWAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 492 TAIWAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 493 TAIWAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 494 TAIWAN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 495 TAIWAN DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 496 TAIWAN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 497 TAIWAN ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 498 TAIWAN DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 499 TAIWAN FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 500 TAIWAN MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 501 TAIWAN DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 502 TAIWAN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 503 TAIWAN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 504 TAIWAN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 505 TAIWAN RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 506 REST OF ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

Abbildungsverzeichnis

FIGURE 1 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: ASIA-PACIFIC VS. REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: MULTIVARIATE MODELLING

FIGURE 8 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: MARKET END-USER COVERAGE GRID

FIGURE 11 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: SEGMENTATION

FIGURE 12 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS IS EXPECTED TO DRIVE THE ASIA-PACIFIC DYSPEPSIA DRUG MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2030

FIGURE 13 NON-ULCER DYSPEPSIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC DYSPEPSIA DRUG MARKET IN 2023 & 2030

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC DYSPEPSIA DRUG MARKET

FIGURE 15 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TYPE, 2022

FIGURE 16 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TYPE, 2023-2030 (USD THOUSAND)

FIGURE 17 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 18 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TYPE, LIFELINE CURVE

FIGURE 19 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , 2022

FIGURE 20 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)

FIGURE 21 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , CAGR (2023-2030)

FIGURE 22 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , LIFELINE CURVE

FIGURE 23 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2022

FIGURE 24 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND)

FIGURE 25 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DRUG TYPE, CAGR (2023-2030)

FIGURE 26 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 27 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2022

FIGURE 28 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2023-2030 (USD THOUSAND)

FIGURE 29 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, CAGR (2023-2030)

FIGURE 30 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, LIFELINE CURVE

FIGURE 31 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2022

FIGURE 32 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)

FIGURE 33 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 34 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY GENDER, 2022

FIGURE 36 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY GENDER, 2023-2030 (USD THOUSAND)

FIGURE 37 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY GENDER, CAGR (2023-2030)

FIGURE 38 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY GENDER, LIFELINE CURVE

FIGURE 39 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY END USER, 2022

FIGURE 40 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 41 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY END USER, CAGR (2023-2030)

FIGURE 42 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY END USER, LIFELINE CURVE

FIGURE 43 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 44 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 45 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 46 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 47 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: SNAPSHOT (2022)

FIGURE 48 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY COUNTRY (2022)

FIGURE 49 ASIA-PACIFIC DYSPEPSIA DRUG DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 50 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY COUNTRY (2022 & 2030)

FIGURE 51 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TYPE (2023-2030)

FIGURE 52 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: COMPANY SHARE 2022 (%)

Detaillierte Informationen anzeigen Right Arrow

Forschungsmethodik

Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.

Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.

Anpassung möglich

Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.

Häufig gestellte Fragen

The Asia-Pacific Dyspepsia Drug Market is projected to grow at a CAGR of 6.1% during the forecast period by 2030.
The future market value of the Asia-Pacific Dyspepsia Drug Market is expected to reach USD 96.81 million by 2030.
The major players in the Asia-Pacific Dyspepsia Drug Market are Bayer AG, Cadila Pharmaceuticals., Sanofi, Lupin., Abbott., Perrigo Company plc, AstraZeneca, Procter & Gamble, and Reckitt Benckiser among others.
The countries covered in the Asia-Pacific Dyspepsia Drug Market are Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, New Zealand, Vietnam, Taiwan, and Rest of Asia-Pacific.